blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2827885

EP2827885 - COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  13.07.2018
Database last updated on 11.09.2024
FormerGrant of patent is intended
Status updated on  25.02.2018
Most recent event   Tooltip29.09.2023Change: Date of oral proceedings 
29.09.2023Deletion: Despatch of minutes of oral proceedings 
Applicant(s)For all designated states
Novo Nordisk A/S
Novo Allé
2880 Bagsværd / DK
[2015/05]
Inventor(s)01 / VILHELMSEN, Thomas
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd / DK
02 / ELIASEN, Helle
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd / DK
03 / HANSEN, Tue
Novo Nordisk
Novo Allé
DK-2880 Bagsværd / DK
 [2015/05]
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Application number, filing date13709231.815.03.2013
[2018/33]
WO2013EP55362
Priority number, dateEP2012016074322.03.2012         Original published format: EP 12160743
US201361748840P04.01.2013         Original published format: US 201361748840 P
EP2013015345931.01.2013         Original published format: EP 13153459
[2015/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013139694
Date:26.09.2013
Language:EN
[2013/39]
Type: A1 Application with search report 
No.:EP2827885
Date:28.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 26.09.2013 takes the place of the publication of the European patent application.
[2015/05]
Type: B1 Patent specification 
No.:EP2827885
Date:15.08.2018
Language:EN
[2018/33]
Search report(s)International search report - published on:EP26.09.2013
ClassificationIPC:A61K38/26, A61P3/10, A61K47/00
[2015/05]
CPC:
A61K38/26 (EP,CN,KR,US); A61K31/20 (EP,US); A61K47/06 (KR);
A61K47/50 (KR); A61K9/16 (KR); A61K9/2013 (EP,CN,KR,US);
A61K9/2077 (EP,CN,KR,US); A61P3/00 (EP); A61P3/04 (EP,KR);
A61P3/10 (EP,KR) (-)
C-Set:
A61K31/20, A61K2300/00 (US,EP);
A61K38/26, A61K2300/00 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ZUSAMMENSETZUNGEN VON GLP-1-PEPTIDEN UND IHRE HERSTELLUNG[2018/09]
English:COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF[2015/05]
French:COMPOSITIONS DE PEPTIDES GLP-1 ET LEUR PRÉPARATION[2015/05]
Former [2015/05]ZUSAMMENSETZUNGEN VON GLP-1-PEPTIDEN UND HERSTELLUNG DAVON
Entry into regional phase22.10.2014National basic fee paid 
22.10.2014Designation fee(s) paid 
22.10.2014Examination fee paid 
Examination procedure22.10.2014Examination requested  [2015/05]
22.05.2015Amendment by applicant (claims and/or description)
09.02.2016Despatch of a communication from the examining division (Time limit: M04)
16.06.2016Reply to a communication from the examining division
26.02.2018Communication of intention to grant the patent
03.07.2018Fee for grant paid
03.07.2018Fee for publishing/printing paid
03.07.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18188815.7  / EP3488857
EP23177173.4  / EP4324475
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.02.2016
Opposition(s)Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
von Kauffmann, Carl
Global IP Group - Teva
Graf-Arco-Straße 3
89079 Ulm / DE
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
CL Sant Gabriel n°50
08950 Esplugues de Llobregat / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.U.
CL Sant Gabriel nº50
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald GmbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
 [2023/40]
Former [2022/22]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
CL Sant Gabriel n°50
08950 Esplugues de Llobregat / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.U.
CL Sant Gabriel nº50
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2022/09]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
6944020 Tel Aviv / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
Avenida Diagonal 123, 11th floor
08005 Barcelona / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.U.
Avinguda de Cornellà 144, 7th floor
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2021/16]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
P.O. Box 3190
5 Basel Street
4951033 Petah-Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
Avenida Diagonal 123, 11th floor
08005 Barcelona / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.U.
Avinguda de Cornellà 144, 7th floor
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2020/01]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
P.O. Box 3190
5 Basel Street
4951033 Petah-Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
Avenida Diagonal 123, 11th floor
08005 Barcelona / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.
Avenida de Cornellà 144, 7th floor
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Maiwald Patent- und Rechtsanwaltsgesellschaft mbH
Elisenhof
Elisenstraße 3
80335 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2019/26]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
P.O. Box 3190
5 Basel Street
4951033 Petah-Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019  21.05.2019  ADMISSIBLE
Galenicum Health S.L.U.
Avenida Diagonal 123, 11th floor
08005 Barcelona / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.
Avenida de Cornellà 144, 7th floor
08950 Esplugues de Llobregat / ES
 03  15.05.2019  21.05.2019  ADMISSIBLE
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Eder, Michael
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 04  15.05.2019  21.05.2019  ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
Former [2019/25]
Opponent(s)01  13.05.2019  16.05.2019  ADMISSIBLE
Teva Pharmaceutical Industries Ltd
P.O. Box 3190
5 Basel Street
4951033 Petah-Tiqva / IL
Opponent's representative
Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
 02  15.05.2019    ADMISSIBLE
Galenicum Health S.L.U.
Avenida Diagonal 123, 11th floor
08005 Barcelona / ES
Opponent's representative
Torrejón-Nieto, Javier
Galenicum Health S.L.
Avenida de Cornellà 144, 7th floor
08950 Esplugues de Llobregat / ES
 03  15.05.2019   
Hexal AG
Industriestrasse 25
83607 Holzkirchen / DE
Opponent's representative
Eder, Michael
df-mp Dörries Frank-Molnia & Pohlman
Patentanwälte Rechtsanwälte PartG mbB
Theatinerstrasse 16
80333 München / DE
 04  15.05.2019    ADMISSIBLE
Generics (U.K.) Limited
Building 4, Trident Place
Mosquito Way
Hatfield Herts AL 10 9UL / GB
Opponent's representative
Ter Meer Steinmeister & Partner
Patentanwälte mbB
Nymphenburger Straße 4
80335 München / DE
03.06.2019Invitation to proprietor to file observations on the notice of opposition
11.10.2019Reply of patent proprietor to notice(s) of opposition
10.08.2020Cancellation of oral proceeding that was planned for 29.09.2020
29.09.2020Date of oral proceedings
28.09.2021Date of oral proceedings
07.12.2021Despatch of minutes of oral proceedings
07.12.2021Despatch of communication that the patent will be revoked
Appeal following opposition03.02.2022Appeal received No.  T0291/22
03.02.2022Payment of appeal fee
19.04.2022Statement of grounds filed
12.09.2024Date of oral proceedings
Fees paidRenewal fee
31.03.2015Renewal fee patent year 03
31.03.2016Renewal fee patent year 04
31.03.2017Renewal fee patent year 05
03.04.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US2009124639  (OYEWUMI MOSES [US], et al) [X] 13,14 * example 8 *;
 [AP]WO2012080471  (NOVO NORDISK AS [DK], et al) [AP] 1-15* the whole document *
OppositionWO2005107462
 WO2006084164
 WO2006124047
 WO2008003050
 WO2012080471
 WO2007146234
 US2009124639
 WO2010020978
 WO2011094531
 EP2827885
 WO2006097537
 WO2008028859
    - STEINERT et al., "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects", Am J Clin Nutr, (20100000), vol. 92, pages 810 - 817, XP002677085

DOI:   http://dx.doi.org/10.3945/ajcn.2010.29663
    - STEINERT et al., "Orally Administered Glucagon-Like Peptide-I Affects Glucose Homeostasis Following an Oral Glucose Tolerance Test in Healthy Male Subjects", Clinical Pharmacology & Therapy, (20090000), vol. 86, pages 644 - 650, XP002635568

DOI:   http://dx.doi.org/10.1038/clpt.2009.159
    - VALENTINO et al., "Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity", Expert Rev Clin Pharmacol, (20100000), vol. 3, no. 1, pages 73 - 88, XP055520546

DOI:   http://dx.doi.org/10.1586/eem.10.33
    - BEGLINGER et al., "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-1 and PYY3-36: A Proof- of-Concept Study in Healthy Subjects", Clin. Pharmacol. Ther., (20080000), vol. 84, no. 4, pages 468 - 474, XP008149454

DOI:   http://dx.doi.org/10.1038/clpt.2008.35
    - R. F. WITKAMP, "Current and Future Drug Targets in Weight Management", Pharm Res, (20110000), vol. 28, pages 1792 - 1818, XP019921746

DOI:   http://dx.doi.org/10.1007/s11095-010-0341-1
    - BHANSALI et al., "Historical Overview of Incretin Based Therapies", JAPI, (20100600), vol. 58, pages 1 - 14, XP055592040
    - BHANSALI et al., "Historical overview of incretin-based therapies", JAPI, (20100600), vol. 58, pages 10 - 14, XP055592040
    - BEGLINGER et al., "Pharmacokinetics and Pharmacodynamic Effects of Oral GLP-t and PYY3-36: A Proof-of-concept Study in Healthy Subjects", Clinical Pharmacology and therapeutics, (20081000), vol. 84, no. 4, pages 468 - 474, XP008149454

DOI:   http://dx.doi.org/10.1038/clpt.2008.35
    - "Granulation", Salman et al., The Handbook of Powder Technology, (20060000), vol. 11, page 1190, XP055592656
    - DILIP M. PARIKH, "Theory of Granulation : An Engineering Perspective", Handbook of Pharmaceutical Granulation Technology third edition, (20050000), page 7, XP055592665
    - ANTONY J HICKEY et al., "Mixing", Pharmaceutical Process Engineering SECOND EDITION, (20100000), page 159, XP055592679
    - STEINERT et al., "Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects", Clinical Pharmacology and Therapeutics, (20090000), vol. 86, no. 6, pages 644 - 650, XP055592565
    - BEGLINGER et al., "Pharmacokinetics and pharmacodynamics Effects of Oral GLP-1 and PYY3-36: A Proof-of-concept Study in Healthy Subjects", Clinical Pharmacology and Therapeutics, (20080000), vol. 84, no. 4, pages 468 - 474, XP008149454

DOI:   http://dx.doi.org/10.1038/clpt.2008.35
    - Anonymous, "History of Changes for Study: NCT01037582, A two part trial investigating the safety of NN9924 in healthy male subjects", Clinicaltrials.Gov, (20091200), pages 1 - 6, URL: https://clinicaltrials.gov/ct2/show/NCT01 037582, XP055592569
    - GRANHALL, C. et al., "Safety and Pharmacokinetics of Single and Multiple Ascending Doses of the Novel Oral Human GLP-1 Analogue, Oral Semaglutide, in Healthy Subjects and Subjects with Type 2 Diabetes", Clinical Pharmacokinetics, (20181200), pages 1 - 11, XP055545538

DOI:   http://dx.doi.org/10.1007/s40262-018-0728-4
    - Close K., "Diabetes Close Up, Baby Steps", Close Concerns, (20110300), no. 106, pages 1 - 50, XP0055592583
    - AUNGST, B.J., "Absorption enhancers: applications and advances", The AAPS Journal, (20110000), vol. 14, no. 1, pages 10 - 18, XP035016737

DOI:   http://dx.doi.org/10.1208/s12248-011-9307-4
    - "Chapter 1, Introduction", Handbook of Pharmaceutical Granulation Technology, SECOND EDITION, Taylor & Francis Group, LLC, (20050000), pages 1 - 6, XP055592603
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.